Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 9:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 87 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Asymptomatic Infections Clear all
Completed Not applicable Interventional

Safety and Efficacy of Polyethylene Glycolated IL-2 (PEG IL-2) Plus Zidovudine or Dideoxyinosine in HIV Positive, Asymptomatic and Symptomatic Individuals

NCT00001997
View directory record Official record
Conditions
HIV Infections
Interventions
Interleukin-2, Polyethylene Glycolated, Zidovudine, Didanosine
Drug
Lead sponsor
Chiron Corporation
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 21, 2026, 9:42 PM EDT
Not listed No phase listed Observational

NGS for Spine Surgery Patients

NCT05013203
View directory record Official record
Conditions
Spine Infection
Interventions
Tissue culture, Next Generation Sequencing
Diagnostic Test
Lead sponsor
Rothman Institute Orthopaedics
Other
Eligibility
18 Years and older
Enrollment
450 participants
Timeline
2021 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 18, 2021 · Synced Jul 21, 2026, 9:42 PM EDT
Terminated Phase 2 Interventional Results available

Asymptomatic Congenital CMV Treatment

NCT03301415
View directory record Official record
Conditions
Congenital Cytomegalovirus Infection
Interventions
Valganciclovir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Day to 30 Days
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
9
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Louisville, Kentucky + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2023 · Synced Jul 21, 2026, 9:42 PM EDT
Completed Phase 1 Interventional

A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Immuno-AG Recombinant HIV gp160 in Asymptomatic HIV Seropositive Individuals

NCT00000633
View directory record Official record
Conditions
HIV Infections
Interventions
gp160 Vaccine (Immuno-AG), Hepatitis B Vaccine (Recombinant)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1998
U.S. locations
2
States / cities
Baltimore, Maryland • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Jul 21, 2026, 9:42 PM EDT
Not listed No phase listed Observational

Asymptomatic Bacteriuria & Risk of Urinary Tract Infection in Renal Transplants

NCT01349738
View directory record Official record
Conditions
Bacteriuria, Urinary Tract Infections, Asymptomatic Infections, Transplantation Infection
Interventions
Antibiotic
Drug
Lead sponsor
Rice, James C., M.D.
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Aug 31, 2011 · Synced Jul 21, 2026, 9:42 PM EDT
Completed Phase 1 Interventional

A Study of Anti-HIV Monoclonal Antibody KD-247

NCT00917813
View directory record Official record
Conditions
HIV Infections
Interventions
KD-247, Physiological saline
Drug
Lead sponsor
The Chemo-Sero-Therapeutic Research Institute
Industry
Eligibility
18 Years to 64 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
15
States / cities
Beverly Hills, California • Burbank, California • Los Angeles, California + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2012 · Synced Jul 21, 2026, 9:42 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Clinical Study of TUTI-16 in Asymptomatic HIV-1 Infected Subjects (THYMON-11001)

NCT01335191
View directory record Official record
Conditions
HIV Infections
Interventions
TUTI-16 (1.0 mg), Placebo
Biological · Other
Lead sponsor
Thymon, LLC
Industry
Eligibility
18 Years to 50 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 14, 2013 · Synced Jul 21, 2026, 9:42 PM EDT
Completed No phase listed Observational

A Clinical Evaluation of Proof Diagnostics Test System Including the Proof Diagnostics Reader and COVID-19 Test

NCT05331976
View directory record Official record
Conditions
COVID-19, Asymptomatic COVID-19
Interventions
Proof Lab Test System
Diagnostic Test
Lead sponsor
Proof Diagnostics
Industry
Eligibility
2 Years and older
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
3
States / cities
Spring Hill, Florida • Statesville, North Carolina • Redmond, Washington
Source: ClinicalTrials.gov public record
Updated Apr 24, 2022 · Synced Jul 21, 2026, 9:42 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

COVID-19 Study Assessing the Efficacy and Safety of Anti-Spike SARS CoV-2 Monoclonal Antibodies for Prevention of SARS CoV-2 Infection Asymptomatic in Healthy Adults and Adolescents Who Are Household Contacts to an Individual With a Positive SARS-CoV-2 RT-PCR Assay

NCT04452318
View directory record Official record
Conditions
Healthy Participants
Interventions
REGN10933 + REGN10987, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
1 Day and older
Enrollment
3,303 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
132
States / cities
Mesa, Arizona • Tucson, Arizona • La Mesa, California + 94 more
Source: ClinicalTrials.gov public record
Updated May 14, 2023 · Synced Jul 21, 2026, 9:42 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Efficacy Study of Preconception Treatment of an Asymptomatic Bacterial Infection in an Infertility Population

NCT01322971
View directory record Official record
Conditions
Vaginosis, Bacterial, Infertility, Miscarriage
Interventions
Metronidazole, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older · Female only
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 19, 2021 · Synced Jul 21, 2026, 9:42 PM EDT
Withdrawn Phase 2 Interventional

Ibrutinib for the Treatment of Patients With B-Cell Malignancies Who Are Infected With Coronavirus Disease 2019 (COVID-19)

NCT04665115
View directory record Official record
Conditions
Asymptomatic COVID-19 Infection Laboratory-Confirmed, B-Cell Neoplasm, Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Small Lymphocytic Lymphoma, Symptomatic COVID-19 Infection Laboratory-Confirmed, Waldenstrom Macroglobulinemia
Interventions
Ibrutinib, Quality-of-Life Assessment
Drug · Other
Lead sponsor
Academic and Community Cancer Research United
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 2, 2022 · Synced Jul 21, 2026, 9:42 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Follow On Community Testing Study To Evaluate The Performance of the Lucira COVID-19 All-In-One Test Kit

NCT04720235
View directory record Official record
Conditions
Covid19, Corona Virus Infection
Interventions
Lucira COVID-19 All-In-One test kit
Device
Lead sponsor
Lucira Health Inc
Industry
Eligibility
14 Years to 75 Years
Enrollment
304 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Los Gatos, California
Source: ClinicalTrials.gov public record
Updated Apr 11, 2021 · Synced Jul 21, 2026, 9:42 PM EDT
Completed Phase 1 Interventional

The Safety and Effectiveness of Different Dose Levels of 1263W94 in the Treatment of Cytomegalovirus (CMV) of the Eyes in HIV-Infected Patients

NCT00002373
View directory record Official record
Conditions
Cytomegalovirus Infections, HIV Infections
Interventions
Maribavir
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
18 Years and older · Male only
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
2
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 21, 2026, 9:42 PM EDT
Completed Phase 2 Interventional

Phase II Study of the Safety and Surrogate Marker Efficacy of Butyldeoxynojirimycin (SC-48334) and AZT in Symptomatic HIV-1 Infected Patients With 200 - 500 CD4+ Cells/mm3. (NOTE: Asymptomatic HIV-1 Infected Patients Also Eligible)

NCT00002079
View directory record Official record
Conditions
HIV Infections
Interventions
Butyldeoxynojirimycin, Zidovudine
Drug
Lead sponsor
G D Searle
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
9
States / cities
San Francisco, California • Tarzana, California • Miami Beach, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 21, 2026, 9:42 PM EDT
Completed Phase 1 Interventional

A Pharmacokinetic and Tolerance Study of Oral Ganciclovir in HIV-Infected Children With Asymptomatic Cytomegalovirus Infection and Low CD4 Cell Counts or Quiescent Cytomegalovirus Disease

NCT00000805
View directory record Official record
Conditions
Cytomegalovirus Infections, HIV Infections
Interventions
Ganciclovir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
14 Days to 20 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1998
U.S. locations
18
States / cities
Los Angeles, California • Oakland, California • San Diego, California + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Jul 21, 2026, 9:42 PM EDT
Completed Phase 3 Interventional

Double-Blind Study of Timunox (Thymopentin) in Asymptomatic HIV-Infected Patients Receiving Either Mono (AZT or ddI) or Combination (AZT / ddI or AZT / ddC) Anti-Retroviral Therapy

NCT00002109
View directory record Official record
Conditions
HIV Infections
Interventions
Thymopentin, Stavudine, Zidovudine, Zalcitabine, Didanosine
Drug
Lead sponsor
Immunobiology Research Institute
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
48
States / cities
Phoenix, Arizona • Irvine, California • Los Angeles, California + 33 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 21, 2026, 9:42 PM EDT
Recruiting Phase 1 Interventional

Bacteriophage Therapy in Spinal Cord Injury Patients With Bacteriuria

NCT06559618
View directory record Official record
Conditions
Bacteriuria, Spinal Cord Injuries, Asymptomatic Bacteriuria, Escherichia Coli
Interventions
Phage Therapy, Placebo
Drug · Other
Lead sponsor
Barbara Trautner
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
St Louis, Missouri • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Jul 21, 2026, 9:42 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Evaluation of the INDICAID™ COVID-19 Rapid Antigen Test

NCT04904510
View directory record Official record
Conditions
Covid19
Interventions
INDICAID™ COVID-19 Rapid Antigen Test
Diagnostic Test
Lead sponsor
University of California, Los Angeles
Other
Eligibility
5 Years and older
Enrollment
297 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Feb 14, 2023 · Synced Jul 21, 2026, 9:42 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Malaria Transmission Studies in Mali

NCT01829737
View directory record Official record
Conditions
Malaria, Falciparum
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Months to 65 Years
Enrollment
534 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 1, 2018 · Synced Jul 21, 2026, 9:42 PM EDT
Terminated Not applicable Interventional Results available

Asymptomatic Colonization With S. Aureus After Therapy With Linezolid or Clindamycin for Acute Skin Infections

NCT01619410
View directory record Official record
Conditions
Skin Diseases, Bacterial, Abscess
Interventions
Linezolid, Clindamycin
Biological
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
2
States / cities
Atlanta, Georgia • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 7, 2019 · Synced Jul 21, 2026, 9:42 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Clinical Simulation Study of a Test Material on the Anterior Nares

NCT05617729
View directory record Official record
Conditions
Colonization, Asymptomatic
Interventions
Saline applied via swab, Povidone-iodine based gel
Other
Lead sponsor
Center for Innovation and Research Organization
Network
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 14, 2022 · Synced Jul 21, 2026, 9:42 PM EDT
Completed Phase 2 Interventional

A Pilot Randomized, Double-Blind, Placebo-Controlled, Parallel Design, Multicenter Trial to Evaluate the Effect of Ranitidine on Immunologic Indicators in Asymptomatic HIV-1 Infected Subjects With a CD4 Cell Count Between 400-700 Cells/mm3

NCT00002106
View directory record Official record
Conditions
HIV Infections
Interventions
Ranitidine hydrochloride
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
4
States / cities
Sherman Oaks, California • Coral Gables, Florida • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 21, 2026, 9:42 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Asymptomatic and Pre-symptomatic Transmission of SARS-CoV-2 in a Community Congregant Setting

NCT05145803
View directory record Official record
Conditions
COVID-19, SARS-CoV2 Infection
Interventions
Polyvinylalcohol strip [diagnostic]
Device
Lead sponsor
Colorado School of Public Health
Other
Eligibility
18 Years and older
Enrollment
3,300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
6
States / cities
Aurora, Colorado • Boulder, Colorado • Colorado Springs, Colorado + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2021 · Synced Jul 21, 2026, 9:42 PM EDT
Completed No phase listed Observational

Clinical Validation of the LumiraDx SARS-CoV-2 & Flu A/B Combo Test

NCT05787444
View directory record Official record
Conditions
SARS-CoV-2, Influenza A, Influenza B, Asymptomatic COVID-19
Interventions
LumiraDx SARS-CoV-2 & Flu A/B
Diagnostic Test
Lead sponsor
LumiraDx UK Limited
Industry
Eligibility
2 Years and older
Enrollment
1,081 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Cullman, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Jul 21, 2026, 9:42 PM EDT